REGULATORY

Chuikyo Begins Discussions on FY2016 NHI Pricing Reform; Drug Pricing Organization to Present Views at Next Meeting

June 11, 2015

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Central Social Insurance Medical Council’s (Chuikyo) Expert Subcommittee on NHI Drug Pricing Affairs began discussing the NHI drug pricing reform scheduled for FY2016 on June 10. The Drug Pricing Organization will present its views on the upcoming reform at…

To read the full story

FY2016 Drug Pricing Reform
August 18, 2015
Abe of JPA Proposes Exempting Ordinary Pharmacies from Medical Fee Cut Rule: Chuikyo
June 12, 2015
NHI Price Revision in FY2017 and Annual NHI Price Revision Should Be Discussed Separately: Shirakawa
June 11, 2015

REGULATORY

Japan Panel Backs Boehringer’s IPF Drug, Moderna COVID Vaccine
April 28, 2026
Japan Allows Flexibility on Pharmacopoeia Test Differences in Supply Crunch
April 28, 2026
Zepbound in Line for OSA Approval after Key Panel Nod
April 27, 2026
LDP Team Urges Patent-Period Price Maintenance, CEA Review in Growth Strategy Proposal
April 27, 2026
Takaichi Says Govt to Weigh Response to MFN Drug Pricing Policy
April 27, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Gene Therapies Expand into AMD, Raising Promise and Cost Concerns

By Shinya Sato

AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…